Lung cancer incidence rates in the United States have undergone a significant transformation over the last several decades, ...

Though the findings are positive overall, survival increases since the mid-1990s are especially notable for more fatal ...

The five-year survival rate for all cancers combined in the US reached a landmark 70% for Americans diagnosed between 2015 ...

An annual report from the American Cancer Society shows that, for the first time, over 70% of Americans diagnosed with cancer ...

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

Five-year relative survival rates for all cancers combined have increased to 70% for people diagnosed during 2015 to 2021 in ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Pancreatic Cancer Action Network Calls for Immediate, Sustained Investment in Research Toward Early Detection and Treatment ...

ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...